Skip to main
ANNX

Annexon, Inc (ANNX) Stock Forecast & Price Target

Annexon, Inc (ANNX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 14%
Sell 14%
Strong Sell 0%

Bulls say

Annexon is a promising biotech company with a promising pipeline of C1q inhibitors targeting various autoimmune disorders, including GA and GBS. However, challenges remain in gaining market share and ensuring financial stability, with concerns about potential vision loss and uncertainties around regulatory approval. Management is working to increase the chances of success in their Phase 3 trials, and the potential market for their lead program in the U.S. and globally is significant.

Bears say

Annexon is facing competition from other companies developing drugs targeting the complement pathway which may limit their market share. Furthermore, their current drugs in development have shown limitations in Phase 2 trials and additional capital may be needed in the future. The company is led by an experienced CEO but may need to differentiate their drugs to stand out in the market and be profitable in the next few years.

Annexon, Inc (ANNX) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Annexon, Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Annexon, Inc (ANNX) Forecast

Analysts have given Annexon, Inc (ANNX) a Buy based on their latest research and market trends.

According to 7 analysts, Annexon, Inc (ANNX) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Annexon, Inc (ANNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.